NASDAQ:RKDA

Arcadia Biosciences Stock Forecast, Price & News

$3.45

+0.40 (+13.11 %)

(As of 01/22/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.05

Now: $3.45▼

$3.57

50-Day Range

$2.47

MA: $2.81▼

$3.29

52-Week Range

$2.30

Now: $3.45▼

$6.48

Volume1.33 million shs

Average Volume707,330 shs

Market Capitalization$37.37 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.62

Arcadia Biosciences, Inc., a consumer-driven agricultural technology company, engages in developing various crop productivity traits primarily in hemp, wheat, and soybean. The company's crop productivity traits are designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. Its products include GoodHemp, a commercial pipeline of non-GMO hemp seed varieties developed with modern crop innovation tools focused on genetic improvement of hemp; GoodWheat that redesigns wheat as a functional food adding value to the wheat supply chain by enabling a range of choices to meet consumer demands; nutritional oils; and HB4, a drought and herbicide tolerant soybean trait. The company has collaborations with Ardent Mills, LLC, Corteva AgriScience, and Arista Cereal Seeds Pty Ltd, and Bay State Milling Company. It operates in the United States, Canada, Africa, and India. The company was founded in 2002 and is headquartered in Davis, California.

MarketRank^™

Overall MarketRank^™

1.35 out of 5 stars

Basic Materials Sector

199th out of 809 stocks

Agricultural Production - Crops Industry

6th out of 21 stocks

3.5 Analyst's Opinion

Consensus Rating
Arcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Arcadia Biosciences has a forecasted upside of 247.8% from its current price of $3.45.
Amount of Analyst Coverage
Arcadia Biosciences has only been the subject of 1 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Arcadia Biosciences has received 274 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Arcadia Biosciences has received 252 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Arcadia Biosciences has received 52.09% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Arcadia Biosciences and other stocks. Vote “Outperform” if you believe RKDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RKDA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Arcadia Biosciences does not currently pay a dividend.
Dividend Growth
Arcadia Biosciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.50% of the stock of Arcadia Biosciences is held by insiders.
Percentage Held by Institutions
Only 8.03% of the stock of Arcadia Biosciences is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Arcadia Biosciences are expected to grow in the coming year, from ($2.20) to ($1.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arcadia Biosciences is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arcadia Biosciences is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arcadia Biosciences has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Agricultural production - crops

Sub-IndustryN/A

SectorBasic Materials

Current SymbolNASDAQ:RKDA

Previous Symbol

CUSIPN/A

CIK1469443

Webwww.arcadiabio.com

Phone530-756-7077

Employees41

Debt

Debt-to-Equity Ratio0.21

Current Ratio2.52

Quick Ratio1.40

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.17 million

Price / Sales31.94

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.96 per share

Price / Book3.59

Profitability

EPS (Most Recent Fiscal Year)($3.37)

Net Income$-28,810,000.00

Net Margins-1,499.85%

Return on Equity-177.69%

Return on Assets-60.11%

Miscellaneous

Outstanding Shares10,832,000

Market Cap$37.37 million

Next Earnings Date3/24/2021 (Estimated)

OptionableNot Optionable

$3.45

+0.40 (+13.11 %)

(As of 01/22/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive RKDA News and Ratings via Email

Sign-up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter.

Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions

How has Arcadia Biosciences' stock price been impacted by COVID-19?

Arcadia Biosciences' stock was trading at $3.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RKDA stock has increased by 8.8% and is now trading at $3.45.
View which stocks have been most impacted by COVID-19.

Is Arcadia Biosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arcadia Biosciences stock.
View analyst ratings for Arcadia Biosciences or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Arcadia Biosciences?

Wall Street analysts have given Arcadia Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arcadia Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Arcadia Biosciences' CEO?

1,448 employees have rated Arcadia Biosciences CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Arcadia Biosciences' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Arcadia Biosciences' next earnings date?

Arcadia Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Arcadia Biosciences.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) announced its quarterly earnings results on Tuesday, November, 17th. The basic materials company reported ($0.60) EPS for the quarter, missing the Zacks' consensus estimate of ($0.54) by $0.06. The basic materials company earned $0.31 million during the quarter, compared to analysts' expectations of $0.97 million. Arcadia Biosciences had a negative net margin of 1,499.85% and a negative return on equity of 177.69%.
View Arcadia Biosciences' earnings history.

When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?

Shares of Arcadia Biosciences reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for RKDA?

2 brokers have issued 1 year price objectives for Arcadia Biosciences' stock. Their forecasts range from $8.00 to $16.00. On average, they expect Arcadia Biosciences' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 247.8% from the stock's current price.
View analysts' price targets for Arcadia Biosciences or view Wall Street analyst' top-rated stocks.

Are investors shorting Arcadia Biosciences?

Arcadia Biosciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 96,800 shares, an increase of 39.7% from the December 15th total of 69,300 shares. Based on an average daily volume of 227,300 shares, the short-interest ratio is presently 0.4 days.
View Arcadia Biosciences' Short Interest.

Who are some of Arcadia Biosciences' key competitors?

Some companies that are related to Arcadia Biosciences include S&W Seed (SANW), Origin Agritech (SEED), Hawaiian Macadamia Nut Orchards (NNUTU), Margo Caribe (MRGO), Scheid Vineyards (SVIN), Shineco (TYHT), Two Rivers Water & Farming (TURV), Yew Bio-Pharm Group (YEWB) and YaSheng Group (HERB).
View all of RKDA's competitors.

What other stocks do shareholders of Arcadia Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), Cannabics Pharmaceuticals (CNBX) and Enerplus (ERF).

Who are Arcadia Biosciences' key executives?

Arcadia Biosciences' management team includes the following people:

Mr. Matthew T. Plavan, Pres, CEO & Director (Age 57, Pay $476.04k)
Ms. Pamela Haley, CFO & Corp. Sec. (Age 50, Pay $268.47k)
Dr. Randall Shultz Ph.D., Chief Technology Officer
Mr. Christopher Williams-Campbell, Head of People
Dr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 55)
Mr. Kevin Hodges, VP of Commercial Operations

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

How do I buy shares of Arcadia Biosciences?

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $3.45.

How big of a company is Arcadia Biosciences?

Arcadia Biosciences has a market capitalization of $37.37 million and generates $1.17 million in revenue each year. The basic materials company earns $-28,810,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Arcadia Biosciences employs 41 workers across the globe.

What is Arcadia Biosciences' official website?

The official website for Arcadia Biosciences is www.arcadiabio.com.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here